Director of the Research and Development Institute
Carroll Group: High Consequence Emerging Viruses Group
HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES
Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system
A prototype lateral flow assay for detection of orthopoxviruses.
Ulaeto DO. et al, (2022), The Lancet. Infectious diseases
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
McNaughton AL. et al, (2022), JCI insight
Convalescent plasma donors show enhanced cross-reactive neutralising antibody response to antigenic variants of SARS-CoV-2 following immunisation.
Harvala H. et al, (2022), Transfusion
Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages.
Prince T. et al, (2022), mSphere
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe A. et al, (2022), JCI Insight, 7